When a patient with antiphospholipid syndrome develops venous thromboembolism — including lower limb deep vein thrombosis — standard VTE anticoagulation protocols do not apply. The underlying autoimmune condition shapes every treatment decision.
This protocol addresses lower limb deep vein thrombosis occurring as part of venous thromboembolism in a patient with antiphospholipid syndrome. The presence of this condition — particularly in its triple-positive antibody profile — is the defining factor that distinguishes this pathway from routine DVT management.
Current evidence-based guidance recommends vitamin K antagonist therapy as the first-line anticoagulation approach for this population — a preference that diverges from the options typically used in VTE without this comorbidity.
Specific agents, dosing, duration, and the complete clinical decision pathway are available in the full protocol below.
DOI: 10.3949/ccjm.91a.22090
Current recommendations favor the use of vitamin K antagonists over DOACs for VTE treatment in these patients, especially those with triple-positive antiphospholipid syndrome (presence of lupus anticoagulant, anticardiolipin, and anti-beta-2-glycoprotein 1 antibodies).
In patients with antiphospholipid syndrome, vitamin K antagonists are suggested over DOACs as first-line treatment (weak recommendation with low-certainty evidence); a vitamin K antagonist can be offered for patients who can't receive or who decline DOACs (weak recommendation, moderate-certainty evidence).
View source ↗